Successful drug response has been correlated with the level of activity and expression of this transporter in tumor cells, but its role in DLBCL remains undefined.33, 34 We first measured SLC22A16 mRNA by quantitative real-time PCR in a panel of DLBCL tumors and cell lines and found that it was expressed at variable levels, with undetectable levels seen in DLBCL cell lines; HL60 cells served as a positive control (Figure 5a). The gene discussed is SLC22A16; the disease is diffuse large B-cell lymphoma.